Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200389618> ?p ?o ?g. }
- W4200389618 abstract "Therapeutic monoclonal antibodies (mAbs) blocking immune checkpoints have been mainly used as monotherapy. Recently, combination therapy targeting multiple immune checkpoints has recently been explored to increase anti-cancer efficacy. Particularly, a single molecule targeting more than one checkpoints has been investigated. As dual blocking of PD-1/PD-L1 and VEGF/VEGFR has demonstrated synergism in anti-tumor activities, we developed a novel bispecific antibody, termed HB0025, which is formed via fusing the domain 2 of vascular endothelial growth factor receptor 1 (VEGFR1D2) and anti-PD-L1 mAb by using mAb-Trap technology. HB0025 almost completely retains the binding affinities and the biological activities in-vitro when compared with the parent anti-PD-L1 mAb or VEGFR1D2 fusion protein. Preclinical data demonstrated that HB0025 was more effective in inhibiting cancer growth than anti PD-L1 mAb or VEGFR1D2 fusion protein. Thus, our bispecific antibody may bring about greater clinical benefits and broader indications." @default.
- W4200389618 created "2021-12-31" @default.
- W4200389618 creator A5010401791 @default.
- W4200389618 creator A5011384463 @default.
- W4200389618 creator A5012449101 @default.
- W4200389618 creator A5018843152 @default.
- W4200389618 creator A5025565506 @default.
- W4200389618 creator A5025996303 @default.
- W4200389618 creator A5027862454 @default.
- W4200389618 creator A5028853083 @default.
- W4200389618 creator A5032423839 @default.
- W4200389618 creator A5033684035 @default.
- W4200389618 creator A5034480243 @default.
- W4200389618 creator A5039875937 @default.
- W4200389618 creator A5047919068 @default.
- W4200389618 creator A5076323336 @default.
- W4200389618 creator A5078125284 @default.
- W4200389618 creator A5091699198 @default.
- W4200389618 date "2021-12-02" @default.
- W4200389618 modified "2023-10-18" @default.
- W4200389618 title "A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities" @default.
- W4200389618 cites W1480371749 @default.
- W4200389618 cites W1489480103 @default.
- W4200389618 cites W1581170315 @default.
- W4200389618 cites W1598118636 @default.
- W4200389618 cites W1975097310 @default.
- W4200389618 cites W1985031636 @default.
- W4200389618 cites W1998400323 @default.
- W4200389618 cites W2000292756 @default.
- W4200389618 cites W2000584529 @default.
- W4200389618 cites W2007108179 @default.
- W4200389618 cites W2033439473 @default.
- W4200389618 cites W2045882462 @default.
- W4200389618 cites W2046527998 @default.
- W4200389618 cites W2049553585 @default.
- W4200389618 cites W2066671159 @default.
- W4200389618 cites W2073113196 @default.
- W4200389618 cites W2089276240 @default.
- W4200389618 cites W2092340284 @default.
- W4200389618 cites W2111290954 @default.
- W4200389618 cites W2128395874 @default.
- W4200389618 cites W2149158668 @default.
- W4200389618 cites W2152897456 @default.
- W4200389618 cites W2155464214 @default.
- W4200389618 cites W2161558877 @default.
- W4200389618 cites W2162889226 @default.
- W4200389618 cites W2164279183 @default.
- W4200389618 cites W2164822601 @default.
- W4200389618 cites W2462633163 @default.
- W4200389618 cites W2493521471 @default.
- W4200389618 cites W2511951051 @default.
- W4200389618 cites W2560367415 @default.
- W4200389618 cites W2605792367 @default.
- W4200389618 cites W2606494852 @default.
- W4200389618 cites W2741365895 @default.
- W4200389618 cites W2747989445 @default.
- W4200389618 cites W2763108561 @default.
- W4200389618 cites W2771409748 @default.
- W4200389618 cites W2807537271 @default.
- W4200389618 cites W2898107810 @default.
- W4200389618 cites W2900088351 @default.
- W4200389618 cites W2941109595 @default.
- W4200389618 cites W2948141873 @default.
- W4200389618 cites W3000443771 @default.
- W4200389618 cites W3011225975 @default.
- W4200389618 cites W3082435441 @default.
- W4200389618 cites W3114498674 @default.
- W4200389618 cites W3128646645 @default.
- W4200389618 cites W4230744147 @default.
- W4200389618 cites W4231178026 @default.
- W4200389618 cites W4231950717 @default.
- W4200389618 cites W4235164288 @default.
- W4200389618 doi "https://doi.org/10.3389/fimmu.2021.778978" @default.
- W4200389618 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34925354" @default.
- W4200389618 hasPublicationYear "2021" @default.
- W4200389618 type Work @default.
- W4200389618 citedByCount "11" @default.
- W4200389618 countsByYear W42003896182022 @default.
- W4200389618 countsByYear W42003896182023 @default.
- W4200389618 crossrefType "journal-article" @default.
- W4200389618 hasAuthorship W4200389618A5010401791 @default.
- W4200389618 hasAuthorship W4200389618A5011384463 @default.
- W4200389618 hasAuthorship W4200389618A5012449101 @default.
- W4200389618 hasAuthorship W4200389618A5018843152 @default.
- W4200389618 hasAuthorship W4200389618A5025565506 @default.
- W4200389618 hasAuthorship W4200389618A5025996303 @default.
- W4200389618 hasAuthorship W4200389618A5027862454 @default.
- W4200389618 hasAuthorship W4200389618A5028853083 @default.
- W4200389618 hasAuthorship W4200389618A5032423839 @default.
- W4200389618 hasAuthorship W4200389618A5033684035 @default.
- W4200389618 hasAuthorship W4200389618A5034480243 @default.
- W4200389618 hasAuthorship W4200389618A5039875937 @default.
- W4200389618 hasAuthorship W4200389618A5047919068 @default.
- W4200389618 hasAuthorship W4200389618A5076323336 @default.
- W4200389618 hasAuthorship W4200389618A5078125284 @default.
- W4200389618 hasAuthorship W4200389618A5091699198 @default.
- W4200389618 hasBestOaLocation W42003896181 @default.
- W4200389618 hasConcept C104317684 @default.
- W4200389618 hasConcept C123894998 @default.
- W4200389618 hasConcept C159654299 @default.